Genome editing strategy opens new perspectives in the treatment of cystic fibrosis

Gene Editing Services

Ubigene has modified over 5000 genes from more than 200 cell lines with our exclusive innovation CRISPR-U™ technology. At the same time, we already provide customers with high quality gene-editing tools for cell or animal research worldwide.

Stable Cell Lines

Knockout Cell Lines

Knockin Cell Lines

Overexpression Cell Lines

Knockdown Cell Lines

iPSC and ESC Gene editing

Cloning Services

Knockout Plasmid

Point Mutation Plasmid

Knockin Plasmid

Overexpression Plasmid

Knockdown Plasmid

Virus Packaging

Lentivirus Packaging

Adenovirus Packaging

Adeno-associated Virus Packaging

CRISPR Library

CRISPR Library In-stock

Customized CRISPR Library

CRISPR Library Screening

Microbe

Gene-editing E.coli

Gene-editing Salmonella

Gene-editing P. aeruginosa

Gene-editing S. aureus

Cell Assay

Cell Proliferation

Cell Migration and Invasion

Cell Cycle

Cell Apoptosis

Detection of Marker Protein Expression

Cytokine Secretion and Enzyme Activity Test

Cytotoxicity Test

EZ-editor™
Gene-editing Series Products

With 14 years of experience, Ubigene has exclusively innovated and developed 6 product lines, fullfilling all kinds of needs from researchers. Experiment process simplified, efficiency improved, achieving our aim of 'Make genome editing easier'!

Red Cotton™ gRNA Plasmid Bank

Regular Plasmid

Lentiviral Plasmid

EZ-editor™ Culture Medium

Transfection Culture Medium

Cell Monoclonal Culture Medium

EZ-Stem™ Cell Culture Medium

EZ-cryo™ Cell Freezing Medium

Knockout-cell-lysate

KO cell lysates (clone)

KO cell lysates (pool)

EZ-editor™ Cell Line

KO Cell Lines

Wild-type Cell Lines

Cas9 Stable Cell Lines

Luciferase Stable Cell Lines

EGFP Stable Cell Lines

EZ-editor™ Kits

Monoclone Genotype Validation Kit (extraction free)

EZ-editor™ Gene Knockout kit

Mouse Genotyping Kit

Lentiviral Packaging Kit

Lentivirus

IVD positive controls

Point Mutation gDNA/Cell Line

Red Cotton Gene knockout Project

Ubigene exclusive KO Cell Line Bank, over 5000 KO cell lines, covering thousands of genes from 8 popular signaling pathways and nearly 100 diseases.

Red Cotton CRISPR Gene Editing Designer

Gene Editing Cell Designer

Gene Editing Point Mutation Designer

Gene Editing Microbe Designer

Gene Editing Tool Kit

Red Cotton Gene knockout Project

Location：Home > About Us > Blogs >

Contact us✖

* Name：

Institution：

* Project Description：

* How would you like us to contact you?

* E-mail：

Phone：

WhatsAPP：

FaceBook Messenger：

Our Solution Specialists will contact you within 2 business days. Of course, you can also tell us when you would like to be contacted:

Select：

Genome editing strategy opens new perspectives in the treatment of cystic fibrosis

The approach adopted by the team of the University of Trento, led by Anna Cereseto, opens new perspectives in the treatment of cystic fibrosis, a genetic disease for which no cure is currently available. The research work was carried out in collaboration with KU Leuven, in Belgium. The research project ("A new gene therapy approach: repairing splicing mutations in the Cftr gene through genome editing") benefited from two years funding amounting to 90,000 euro from the Italian foundation for research on cystic fibrosis (Fondazione ricerca fibrosi cistica), with the participation of the Cystic fibrosis association of Trentino (Associazione trentina fibrosi cistica). The results of the study were published today in Nature Communications, an open access journal.

The disease is caused by a mutation of the gene that produces Cftr (the cystic fibrosis transmembrane conductance regulator), whose malfunctioning affects multiple organs, especially the lungs. The UniTrento/KU Leuven research team adapted the Crispr-Cas system, the molecular scissors that are revolutionizing biomedicine, to permanently edit at least two types of the mutation that cause cystic fibrosis. In particular, the technique is called "SpliceFix" because it fixes the gene and restores the protein production mechanism at the same time.

Giulia Maule, doctoral student in Biomolecular sciences at the University of Trento and first author of the article, explained:

"We have devised a genome editing strategy based on Crispr-Cas to permanently remove two different mutations that cause the disease. Crispr-Cas works like a genomic scalpel to cut out the mutated elements with extreme accuracy. We demonstrated that our repair strategy works on patient-derived organoids and with a high level of precision: it targets only the mutated sequences, leaving non-mutated DNA untouched".

The young researcher underlines a novel aspect of the study: "Instead of animal models, we have used organoids that we developed from the patients' cells, a choice that allowed us to verify the efficacy of the molecular strategy in a context that is very similar to that of the patients with cystic fibrosis".

Cystic fibrosis is also called the invisible disease because it doesn't show on the outside, and yet it takes a huge toll on the lives of the people it affects. Most of all, they have lung and digestive problems. The disease is inherited from parents. In Italy, about one in 25 people is a carrier. This means that a couple of carriers has one chance in four to have a child with the disease. There are about 6,000 people with cystic fibrosis in Italy, and 200 new cases every year.